Skip to content
Leo Pharma
-
LEO Pharma acquires Replay to advance their gene therapy pipeline for rare genetic skin diseases
LEO Pharma will gain access to Replay’s proprietary high-payload herpes simplex virus (HSV) delivery platform, an innovative technology designed to deliver large therapeutic genes directly into skin cells.